Phase 2 Study of HKI-272 in Subjects with Advanced Breast Cancer

Mise à jour : Il y a 4 ans
Référence : EUCTR2005-003098-26

Femme Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

Determine the sixteen (16) week progression-free survival (PFS) rate for HKI-272 in women with advanced breast cancer.


Critère d'inclusion

  • Breast cancer is the most frequently diagnosed malignancy and the second most common cause of cancer related deaths in women. HER2 is a member of the epidermal growth factor receptor (EGFR) family that includes EGFR/HER1, HER2, HER3 and HER4, all being receptor tyrosine-protein kinases. The oncogenic role of HER2 has been extensively documented in breast cancer, where it is overexpressed in 25% to 30% of breast cancers